Reinduction of Complete Remissions Using 19-28z CAR T-Cell Therapy in Relapsed B-Cell ALL


Reinduction of Complete Remissions Using 19-28z CAR T-Cell Therapy in Relapsed B-Cell ALL
Slides from a presentation at ASH 2013 and transcribed comments from recent interviews with Hagop M Kantarjian, MD (1/29/14) and David L Porter, MD (3/3/14)
Davila M et al. Safe and effective re-induction of complete remissions in adults with relapsed B-ALL using 19-28z CAR CD19-targeted T cell therapy. Proc ASH 2013;Abstract 69.

Dr Kantarjian is Chairman and Professor in the Leukemia Department at The University of Texas MD Anderson Cancer Center in Houston, Texas.

Dr Porter is Jodi Fisher Horowitz Professor of Leukemia Care Excellence and Director of Blood and Marrow Transplantation at the University of Pennsylvania Health System's Abramson Cancer Center in Philadelphia, Pennsylvania.